Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Mais filtros

Base de dados
Intervalo de ano de publicação
Blood Cells Mol Dis ; 74: 1-4, 2019 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-30293687


OBJECTIVE: Portal vein thrombosis (PVT) has been described as a rare complication after splenectomy. PVT associated risk factors after splenectomy in hematological disorders are poorly recognized. The aim of this study was to assess the prevalence and risk factors of PVT incidence in splenectomized patients. METHODS: One hundred twelve splenectomized patients with various hematologic diseases between 2008 and 2018 were enrolled in this study. Diagnosis was confirmed by Doppler ultrasonography (DUSG) and risk factors for PVT were sought based on the comparison of clinical and laboratory features between patients without and with PVT. RESULT: PVT was diagnosed in 4 (3.57%) patients in spite of receiving antiplatelet therapy. Patients with PVT were ß-thalassemia major (n = 2) and ß-thalassemia intermedia (n = 2). ß-thalassemia patients had a 3.5 times higher odds for PVT (95% CI: 2.41-5.33). No significant differences between patients with and without PVT in terms of age, gender and laboratory features were found. CONCLUSION: According to our data, ß-thalassemia, especially intermediate form, may be a risk factor for PVT and it can occur in spite of receiving antiplatelet therapy. Given that ß-thalassemia patients are at risk, early PVT detection may be useful for reduction of fatal PVT complication in splenectomized patients.

Doenças Hematológicas/complicações , Veia Porta/patologia , Esplenectomia/efeitos adversos , Trombose Venosa/etiologia , Estudos de Casos e Controles , Humanos , Incidência , Estudos Retrospectivos , Fatores de Risco , Trombose Venosa/diagnóstico , Talassemia beta/complicações
Fundam Clin Pharmacol ; 30(1): 70-5, 2016 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-26463007


The objective of this study was to compare the effect of L-epinephrine plus dexamethasone vs. dexamethasone for treatment of croup in children. A randomized, double-blind clinical trial was implemented on 174 patients with croup, aged from 6 months to 6 years, and admitted to the Amir Kabir Pediatric Hospital (Arak, Iran). After randomized allocation, patients were administered dexamethasone, and then, they received either saline or L-epinephrine. Westley croup scores, heart rate, respiratory rate, and blood pressure were recorded every half an hour for a total of 120 min. There was a significant difference in mean of croup scores between two groups (P < 0.009). In addition, a significant difference was seen on mean of heart rate between two groups (P < 0.026). Our results showed a considerable difference in reduction of velocity of croup scores in patients who received nebulized L-epinephrine compared to patients who received placebo.

Agonistas Adrenérgicos beta/uso terapêutico , Crupe/tratamento farmacológico , Epinefrina/uso terapêutico , Administração por Inalação , Agonistas Adrenérgicos beta/administração & dosagem , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/uso terapêutico , Pressão Sanguínea/efeitos dos fármacos , Criança , Pré-Escolar , Crupe/metabolismo , Crupe/fisiopatologia , Dexametasona/administração & dosagem , Dexametasona/uso terapêutico , Método Duplo-Cego , Quimioterapia Combinada , Epinefrina/administração & dosagem , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Lactente , Injeções Intramusculares , Masculino , Nebulizadores e Vaporizadores , Taxa Respiratória/efeitos dos fármacos , Índice de Gravidade de Doença
J Neuroimaging ; 17 Suppl 1: 16S-21S, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17425729


Magnetic resonance imaging (MRI) has emerged as a powerful noninvasive tool to assist in the diagnosis and monitoring of multiple sclerosis (MS). In addition, investigators have used MRI metrics as supportive outcome measures to explore drug efficacy in clinical trials. Conventional MRI surrogates provide information at the macroscopic level but lack sensitivity and specificity in identifying the full extent of underlying MS pathology. They also show relatively weak relationships to clinical status such as predictive strength for clinical change. Advanced MRI techniques involving quantitative measures of diffuse damage in normal appearing (NA) white matter (WM) and gray matter (GM) may help in resolving this apparent clinical MRI paradox. T2 hypointensity has been described in the GM of patients with MS and has been linked to physical disability, cognitive dysfunction, and brain atrophy. While this T2 hypointensity is thought to represent iron deposition, this awaits pathologic confirmation. Advanced MRI measures of iron deposition such as R2, R2*, R2' relaxometry, 3T imaging and other new approaches are beginning to be applied to studies of MS and should yield interesting information. Both T1 and T2 relaxometry have a role in detecting damage in NA brain tissue that escapes detection by conventional MRI lesion measures. For example, T2 mapping may allow an assessment of myelin content in NAWM. In this review, we will focus on MRI advances in the last 10 years pertaining to T1 and T2 measures of diffuse GM and WM damage.

Encéfalo/patologia , Imagem por Ressonância Magnética/métodos , Esclerose Múltipla/patologia , Atrofia , Encéfalo/metabolismo , Humanos , Ferro/metabolismo , Esclerose Múltipla/metabolismo